A B S T R AC T
Background. It has been recently mathematically demonstrated that the percentage increase in serum creatinine (SCr) can delay acute kidney injury (AKI) diagnosis in patients with previous chronic kidney disease (CKD) . Based on creatinine (Cr) kinetics, it was suggested a new AKI classification using absolute increase in SCr elevation over specified time periods. However, this classification has not been evaluated in clinical studies. Methods. A prospective cohort study evaluated myocardial infarction patients during the first 7 days of hospital stay with daily SCr measurements. They were classified using Kidney Disease Improving Global Outcomes (KDIGO) and Cr kinetics systems. Both classifications were compared by net reclassification improvement (NRI) and area under the receiver operator characteristic (AuROC) curve regarding hospital mortality.
Results. A total of 584 patients were included, of which 34.1% had previous CKD. Patients had more AKI by KDIGO than by Cr kinetics criteria (25.7 versus 18.0%, P < 0.001) and 81 patients (13.9%) had different AKI severity classification. Patients with AKI by KDIGO criteria and non-AKI by Cr kinetics had higher hospital mortality rates than patients with non-AKI using both classifications [adjusted mortality odds ratios (ORs): 4.753; 95% confidence interval (CI): 1.119-9.023, P = 0.014]. In patients with previous CKD, NRI analysis was 6.2% favoring Cr kinetics criteria. However, there was no difference using the AuROC curve analysis. In patients with no previous CKD, NRI analysis was 33.0%, favoring KDIGO, and this was in accordance with a better AuROC curve (0.828 versus 0.664, P < 0.05). Conclusions. AKI classification proposed by a Cr kinetics model can be superior when diagnosing patients with previous CKD. However, KDIGO had a better performance in patients with no previous CKD.
I N T R O D U C T I O N
Acute kidney injury (AKI) is a common occurrence in hospitalized patients [1] , especially in some populations, such as critically ill patients [2] , those with heart [3, 4] or chronic liver disease [5] . In spite of the critics regarding the use of serum creatinine (SCr) as a renal function marker [6] , in clinical practice AKI diagnosis is still based on SCr levels and urine output [7] . Recently, the 'Kidney Disease Improving Global Outcomes (KDIGO)' guidelines defined and staged AKI based on modifications of RIFLE (Risk, Injury, Failure, End Stage) and Acute Kidney Injury Network (AKIN) classification systems [8] . Due to the association with several outcomes, including mortality, this classification has been used in many studies and is now more often used in clinical practice.
Although there are significant differences between RIFLE and AKIN criteria, both are based on the percentage or absolute SCr increase over a reference value to ascertain AKI diagnosis and severity. An absolute increase in SCr is used to diagnose and stage AKI in only two clinical situations in AKIN classification: an acute increment of 0.3 mg/dL classifies patients with stage 1 AKI; also, in both systems, an acute increase in SCr of 0.5 mg/dL in patients with SCr >4 mg/dL is considered AKI stage 3 or RIFLE class F.
Recently, Waikar and Bonventre [9] demonstrated that the percentage increase in SCr elevation can delay AKI diagnosis in patients with previous chronic kidney disease (CKD) and higher baseline SCr. Based on Cr kinetics, these authors suggested a new AKI classification using absolute increase in SCr elevation over specified time periods (see Table 1 ). It was suggested that this new classification could have better performance in patients with acute-on-CKD. Although mathematically reasonable, there have been no studies evaluating this new classification performance in predicting clinical outcome.
To compare KDIGO-AKI classification with Cr kineticsbased system, we have chosen a prospective cohort of patients with ST-segment-elevation myocardial infarction (STEMI). AKI is a common event in STEMI patients [3] . Also, CKD can be present in nearly one-third of acute myocardial infarction patients [10] . Moreover, hospitalized patients with acute myocardial infarction (AMI) are submitted to several procedures and complications related to AKI [coronary artery bypass grafting (CABG), catheterization, heart failure and drug nephrotoxicity].
Other specific characteristics of acute myocardial infarction patients include: (i) hospital admission occurs soon after an acute event, so community-acquired AKI is unlikely and hospital admission SCr more likely reflects baseline glomerular filtration rate (GFR) and (ii) a large previous study demonstrated that absolute increase in SCr was associated with mortality in patients suffering acute myocardial infarction [11] .
These characteristics make STEMI patients adequate to compare the AKI classification proposed by the Cr kinetics model against consensus-based and validated AKI criteria (KDIGO).
M AT E R I A L S A N D M E T H O D S
This study was performed in a reference Hospital in Fortaleza, Brazil. This is a cardiopulmonary specialized hospital used by an estimated population of 3 million people. Patients were enrolled from the Emergency Department (ED) between January 2010 and December 2011. All patients with a diagnosis of STEMI at presentation to the ED were initially enrolled.
Patients with CKD undergoing maintenance dialysis therapy, previous renal transplantation, those whose SCr was not measured daily and whose hospital stay was <48 h were excluded. Also, due to a known transient reduction in SCr after surgical procedure [12] , patients submitted to CABG were excluded. Admission GFR was calculated according to the CKD-Epidemiology Collaboration equation [13] and assumed to be the baseline GFR to classify AKI. SCr was measured at ED admission and early every morning. When difference between the two first SCr measurements was <6 h apart, only the first one was recorded and the second SCr was the one collected between 24 and 30 h after admission. If the difference between admission SCr and the second measurement was 6-18 h apart and if there was any increment in the second measured SCr, we estimated the SCr at 24 h after admission. This estimation was performed by calculating the Cr clearance reduction from admission to second SCR measurement, using the following validated equation [14] :
Mean SCR Â ð1 À 24 Â DSCrÞ DtimeðhÞ Â MaxDSCr=day where KeGFR: estimated glomerular filtration rate; admSCr: admission serum creatinine; CrCl: creatinine clearance at ED admission; Mean SCr: arithmetic mean of two first serum creatinine levels; ΔSCr: difference between second and first serum creatinine levels; MaxΔSCr/day: maximal serum creatinine increment in a day considering no GFR (here, we considered it as 1 mg/dL). The same Cr clearance reduction rate was assumed to back calculate the SCr after 24 h of admission. These estimated SCr were used only if it was greater than the measured one. We included variables collected at the ED and during hospitalization. The following parameters were collected in the ED: age, sex, symptom time, door-to-balloon time, previous history of diabetes mellitus, arterial hypertension, SCr and drug administration. GRACE risk score was calculated in the ED. During the hospital stay, patients were evaluated daily and the laboratory features were collected. Length of hospital stay (LOS) was recorded and renal function recovery was considered when the last SCr was not >0.3 mg/dL in comparison with the one at admission. The Institutional Ethical Committee approved this study.
AKI classifications
Each patient was evaluated and classified daily, based on routine assessment of serum Cr using the two classification systems: KDIGO and creatinine (Cr) kinetics (Table 1) . SCr was measured and evaluated daily with a maximum variation of 2 h for blood sample collections at daytime. As suggested by Cr kinetics model, SCr increments were considered with a maximum time period of 48 h between them. For comparison between different classifications, the worst AKI classification in the first 7 days of hospital stay was selected.
Statistical analysis
Analysis was performed using SPSS 19.0 for Windows. All variables were tested for normal distribution using the Kolmogorov-Smirnov test. Normally or near-normally distributed variables are reported as means with standard deviations (SDs). Categorical data were reported as proportions and compared using Fisher's exact test. Discrimination was assessed by the area under the receiver operator characteristic (AuROC) curve and comparison of discriminatory capacity was performed using the non-parametric method. Furthermore, we determined the net reclassification improvement (NRI) between KDIGO and Cr kinetics criteria, defining KDIGO as the classification variable and Cr kinetics criteria as the reclassification variable. By calculating the NRI, we were able to quantify the degree to which the new criteria were driving correct movements between categories [15] . The sum of NRI was calculated by adding the net reclassification ( proportion of individuals moving up minus the proportion moving down) of the event (death) and non-event group. An NRI can be interpreted as the percentage by which the net classification has improved with the new criteria. These comparisons were performed in all patients and according to the baseline GFR. Mortality risk according AKI stage was adjusted for GRACE risk and acute physiology and chronic health evaluation (APACHE)-II scores, both censored for renal function variables, using a binary regression logistic model. Data are presented as odds ratios (ORs) with 95% confidence intervals (CI). A P-value of < 0.05 was considered statistically significant for all comparisons.
R E S U LT S
Overall, 584 patients (67.1% males) were included in the final analysis with a mean age of 63.1 ± 12.6 years. Diabetes mellitus was present in 34.2% and hypertension in 62.0% of patients. At admission, a GFR < 60 mL/min was present in 199 (34.1%) patients. Most patients were submitted to primary percutaneous transluminal coronary angioplasty (PTCA)-n = 526, 90.1%. Hospital mortality rate was 13.2% and mean hospital stay was 6.8 ± 2.6. Patient characteristics are shown in Table 2 . Nine patients had the calculated SCr levels used, instead of the 
r e a t i n i n e k i n e t i c s i n A K I measured one in the first 24 h and only two had change in AKI stage/timing of diagnosis.
Incidence of AKI
In the first 7 days after hospital admission, patients were more often diagnosed as AKI by KDIGO than by Cr kinetics criteria (25.7 versus 18.0%, P < 0.001). Of these, 84 patients had reduced urine output (<400 mL/day) during at least 1 day and 18 patients needed renal replacement therapy during hospital stay. A comparison of AKI stage between KDIGO and Cr kinetics criteria is shown in Table 3 (All patients' section). Overall, in the first 7 days, 81 (13.9%) patients had different AKI classifications. The main differences were: (i) some patients classified as AKI stage 1 by KDIGO had non-AKI by Cr kinetics criteria; and (ii) patients had more severe AKI stage by Cr kinetics criteria (Table 3) .
AKI classifications, LOS and hospital mortality
Hospital mortality according to the two different criteria is shown in Table 4 . The mortality of patients with any AKI stage 7 days after hospital admission was higher when applying Cr kinetics rather than KDIGO criteria, but the difference was not statistically significant (35.2 versus 30.7%, respectively, P = 0.497).
The NRI analysis of all patients is shown in Table 5 .
kinetics to stage 0 were survivors (n = 35) and the majority of these patients (n = 33) had complete renal function recovery at hospital discharge. The NRI was 2.6% (1.4-2.9) favoring KDIGO system. Patients with AKI by KDIGO criteria and non-AKI by Cr kinetics had a higher adjusted hospital mortality rate and LOS than patients with non-AKI using both classifications (adjusted mortality OR: 4.753; 95% CI: 1.119-9.023, P = 0.014; LOS 7.3 ± 2.9 versus 6.1 ± 2.8, P = 0.032). Differences between AuROC curves were not significant (AuROC 0.731 and 0.687 for KDIGO and Cr kinetics, respectively, P = ns) (Supplementary data, Figure S1 ). Renal function recovery rate was not different between survivors with severe AKI-18/26 patients with AKI stage 2 or 3 by KDIGO and 21/ 28 by Cr kinetics, P = 0.741.
AKI classifications and hospital mortality in patients with admission GFR <60 mL/min/1.73 m 2 When considering only patients with admission GFR < 60 mL/min/1.73 m 2 (n = 199), AKI in was diagnosed in 35.7% of patients by KDIGO and 31.2% by Cr kinetics criteria, P = ns. Mortality rates according to AKI diagnosis and its severity were very similar in patients with AKI by KDIGO or Cr kinetics (Table 4) . In CKD patients, there was no significant increase in mortality from stage 2 to stage 3 when applying either system.
Of 199 patients with admission GFR < 60 mL/min/1.73 m 2 , 32 patients were misclassified between KDIGO and Cr kinetics (Tables 3 and 6 ). Similar to the general population, many patients with AKI stage 1 by KDIGO had non-AKI by Cr kinetics criteria. Furthermore, patients had a higher AKI severity when classified by Cr kinetics in comparison with KDIGO criteria.
The NRI analysis for patients with admission GFR < 60 mL/min/1.73 m 2 was 6.2% (3.6-8.2), favoring Cr kinetics criteria (Table 6 ). Of 16 patients correctly reclassified by Cr kinetics criteria: seven non-survivors were up-reclassified from stage 2 to stage 3, and 7 survivors were down-reclassified from stage 1 to stage 0.
When analyzing by discriminatory capacity for mortality, the two systems had very similar performance (AuROC 0.653 and 0.645 for KDIGO and Cr kinetics, respectively, P = ns) (Supplementary data, Figure S2 ). Remarkably, both systems showed poor discriminatory capacity in patients with admission GFR < 60 mL/min/1.73 m AKI classifications and hospital mortality in patients with admission GFR > 60 mL/min/1.73 m 2 AKI incidence was almost twice-from 12.1 to 20.5%-when the KDIGO criteria were applied, when compared with Cr kinetics (P < 0.001). Overall, 49 (12.7%) patients were reclassified by Cr kinetics criteria. The majority of reclassified patients (n = 35) were at KDIGO stage 1 and Cr kinetics stage 0. These patients had a higher adjusted hospital mortality rate than patients with non-AKI using both classifications (OR: 11.166 95% CI: 3.534-30.352, P < 0.001). The NRI analysis in patients with previous normal GFR demonstrated an NRI of 33.0% (17.9-37.6) favoring KDIGO. The main failure of Cr 
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kinetics performance was an incorrect underestimation of AKI severity in non-survivors (Table 7) . Moreover, KDIGO criteria showed a better discriminatory capacity for mortality than Cr kinetics criteria (AuROC 0.828 versus 0.664, P = 0.03) (Supplementary data, Figure S3 ).
Timing to AKI classification
Patients with the same AKI classification in both KDIGO and Cr kinetics systems were evaluated regarding time from hospital admission to worst AKI classification. As shown in Figure 1 , there was no clear advantage in Cr kinetics over KDIGO system regarding early AKI diagnosis. The main difference observed was that some patients were diagnosed with AKI in the first 48 h by KDIGO, but not by Cr kinetics.
D I S C U S S I O N
In the present study, a new proposed AKI system classification based on SCr kinetics was evaluated regarding its capacity to diagnose AKI and predict in-hospital mortality. When evaluating a cohort of STEMI patients, Cr kinetics criteria, in comparison with KDIGO criteria, were less sensitive in diagnosing AKI. More importantly, Cr kinetics was a better predictor of severity in patients with admission GFR < 60 mL/min/1.73 m 2 when evaluated by NRI, but had an inferior performance in those patients with a basal GFR >60 mL/min.
The recent AKI classification proposed by Waikar and Bonventre [9] was based on a SCr kinetics model. This system considers absolute variations in SCr over defined time intervals (Table 1 ). The possible advantage over KDIGO criteria could be observed in patients with previous CKD in whom any percentage reduction in GFR would lead to a slower rate of rise in SCr percentage compared with a patient with non-CKD at baseline. This could result in a different classification of AKI severity, despite a similar renal lesion severity.
To assess whether this approach would result in a better prediction of clinical outcome, we performed a prospective study with Cr measurements at 24-h intervals in a population Cr kinetics is the reclassification system. Gray are patients correct reclassified.
with a higher prevalence of CKD, susceptible to AKI and reasonable estimation of basal GFR by using hospital admission GFR. Patients presenting with STEMI constitute a relatively homogeneous population that arrive at the hospital quickly after the acute event, so admission SCr will generally reflect baseline renal function. In our study, nearly one-third of patients had admission GFR < 60 mL/min/1.73 m 2 .
Because it was not technically viable to measure the second SCr exactly 24 h after ED admission, we estimated the second SCr in those with an interval of 6-18 h between two first SCr measurements. This was performed using a validated equation to calculate GFR in AKI considering GFR decrement constant to estimate the SCr 24 h after admission. This is unlikely to change data interpretation, as only two patients had different AKI classification or timing on diagnosis using this estimation.
KDIGO criteria were more sensitive than Cr kinetics criteria in diagnosing AKI. The main reason for this difference was the increment of 0.3 mg/dL in SCr over 48 h, sufficient to classify AKI stage 1 by KDIGO. The same increment must occur within only 24 h or an increment of 0.5 mg/dL must occur in 48 h to be diagnosed as AKI by Cr kinetics. More than half of the patients diagnosed as having AKI stage 1 by KDIGO had non-AKI by Cr kinetics. This difference can also explain the early AKI diagnosis by the KDIGO system in the first 2 days of hospital stay. According to the kinetic model, stage 1 corresponds to a 19-39% reduction in GFR [9] . Patients with a SCr increment of 0.3 mg/ dL in 48 h have a GFR reduction <19%, but this can still have a significant impact on prognosis. According to our data, AKI patients identified only by KDIGO criteria had a significant increment in mortality. This finding is in accordance with another large study that demonstrated that SCr increments of only 0.3 mg/dL had an impact on prognosis even at a long-term followup after AMI [16] .
Another main difference observed was an increase in AKI severity when adopting Cr kinetics criteria. The majority of patients with AKI stage 2 by KDIGO criteria were classified as stage 3 using Cr kinetics criteria. Nearly half of these up-reclassification cases were correct, mainly in patients with admission GFR < 60 mL/min/1.73 m 2 . When analyzed by NRI, Cr kinetics had a better performance in patients with admission GFR < 60 mL/min/1.73 m 2 , with a NRI >13%. However, this improvement was not reflected by discriminatory capacity and both systems had similar AuROC in patients with admission GFR < 60 mL/min/1.73 m 2 . In fact, no system had a satisfactory performance in this group of patients. There was no stepwise increment in mortality according to AKI severity, and AuROC had a moderate performance at best. There was no significant difference in mortality when patients with admission GFR < 60 mL/min/1.73 m 2 achieved AKI stage 3 in comparison with stage 2. To the best of our knowledge, there has been no study evaluating the new AKI classifications (RIFLE, AKIN or KDIGO) in patients with reduced baseline GFR. Recently, Wu et al. [17] demonstrated that acute-on-CKD patients had worse outcomes than patients with CKD only, but no evaluation of AKI severity was performed.
In patients with normal basal renal function, only onethird of patients with AKI by KDIGO also had AKI by Cr kinetics. Moreover, patients with normal baseline GFR had less severe AKI. By KDIGO criteria, only 5% had AKI stages 2 or 3 and 16% had AKI stage 1. Although less severe, it is important to identify these patients, because a 7-fold increase in mortality was present in those with AKI only by KDIGO when compared with no AKI by both systems. When applied to patients with admission GFR > 60 mL/min, Cr kinetics was inferior to KDIGO criteria. In these patients, NRI (19.3%) favored KDIGO criteria. The main difference was that Cr kinetics incorrectly down-reclassified 31.0% of non-survivor patients with previous normal renal function. This difference is reflected in a better KDIGO discriminatory capacity than Cr kinetics when AuROC is analyzed.
This down-reclassification by Cr kinetics can be partially explained by the interval required to diagnose and classify AKI. The kinetic model as proposed assumes that SCr reaches a new steady state after 48 h. This assumption is valid when renal lesion is single and over a brief time interval. This is not the case in many clinical situations when renal aggression can occur over several days and in multiple events in the same patients.
For instance, a patient that received contrast and has an increment of 0.3 mg/dL after 48 h is then submitted to cardiac surgery, and on the following day, has another increment of 0.2 mg/dL. This same patient, after 4 days of a nephrotoxic antibiotic, has another increment of 0.3 mg/dL. After 7 days, his SCr increases over 0.8 mg/dL from baseline. This patient is not diagnosed as AKI by Cr kinetics, but can have AKI stage 2 or 3 by KDIGO criteria. Supporting this fact, 24.1% of nonsurvivor patients with previous normal renal function had AKI only by KDIGO criteria.
Recently, Wang et al. [18] demonstrated that absolute changes in SCr are better than current KDIGO criteria in predicting mortality. However, in the abovementioned study, the absolute difference in SCr was calculated considering the lowest and peak SCr during hospitalization, with no time limits. Although Cr kinetics model attempts to correlate SCr increment over time, more explicit criteria using ΔSCr/time period must be further explored, preferably using time periods longer than 48 h.
The main limitation of the present study is that only STEMI patients were studied. The reasons for studying this population are explained above, but this limits the validity of this study, especially regarding critically ill patients, in whom fluid balance alters the SCr concentration [19] . Moreover, although we have chosen STEMI patients because hospital admission SCr more likely reflects basal GFR, we cannot exclude the possibility that some patients had community-acquired AKI and basal GFR was underestimated. Another point is the lack of a more sensitive renal lesion marker that could help to better evaluate timing of AKI diagnosis with both KDIGO and Cr kinetics criteria. Finally, the relatively small number of patients is a limitation, but it is justified by the need of a prospective study to evaluate Cr kinetics criteria. In fact, requirement of daily SCr measurements can limit its use in clinical practice, mainly outside critical care units where daily SCr measurements is not a routine.
In conclusion, AKI classification proposed by a Cr kinetic model appears to be superior in patients with baseline GFR is <60 mL/min/1.73 m 2 when analyzed by NRI, but not by ROC analysis. However, KDIGO was clearly superior in patients with baseline GFR <60 mL/min/1.73 m 2 . Classification systems must be better evaluated in acute-on-CKD patients.
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